India Peptide Antibiotics Market Size & Outlook, 2025-2030
Related Markets
India peptide antibiotics market highlights
- The India peptide antibiotics market generated a revenue of USD 256.2 million in 2024 and is expected to reach USD 404.2 million by 2030.
- The India market is expected to grow at a CAGR of 7.9% from 2025 to 2030.
- In terms of segment, non-ribosomal synthesized peptide antibiotics was the largest revenue generating product in 2024.
- Non-Ribosomal Synthesized Peptide Antibiotics is the most lucrative product segment registering the fastest growth during the forecast period.
Peptide antibiotics market data book summary
| Market revenue in 2024 | USD 256.2 million |
| Market revenue in 2030 | USD 404.2 million |
| Growth rate | 7.9% (CAGR from 2025 to 2030) |
| Largest segment | Non-ribosomal synthesized peptide antibiotics |
| Fastest growing segment | Non-Ribosomal Synthesized Peptide Antibiotics |
| Historical data | 2018 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Ribosomal Synthesized Peptide Antibiotics, Non-Ribosomal Synthesized Peptide Antibiotics |
| Key market players worldwide | Pfizer Inc, Merck & Co Inc, AbbVie Inc, GSK PLC, Sandoz Group AG ADR, Novo Holdings, Theravance Biopharma Inc |
Other key industry trends
- In terms of revenue, India accounted for 5.2% of the global peptide antibiotics market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, China peptide antibiotics market is projected to lead the regional market in terms of revenue in 2030.
- India is the fastest growing regional market in Asia Pacific and is projected to reach USD 404.2 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Peptide Antibiotics Market Scope
Peptide Antibiotics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Novo Holdings | View profile | 101-250 | Hellerup, Hovedstaden, Denmark, Europe | https://www.novoholdings.dk |
| Sandoz Group AG ADR | View profile | - | - | - |
| Theravance Biopharma Inc | View profile | 99 | Ugland House, South Church Street, George Town, PO Box 309, Grand Cayman, Cayman Islands, KY1-1104 | https://www.theravance.com |
| GSK PLC | View profile | 70200 | 980 Great West Road, Brentford, Middlesex, United Kingdom, TW8 9GS | https://www.gsk.com |
| Merck & Co Inc | View profile | 72000 | 126 East Lincoln Avenue, Rahway, NJ, United States, 07065 | https://www.merck.com |
| Pfizer Inc | View profile | 88000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | https://www.pfizer.com |
| AbbVie Inc | View profile | 50000 | 1 North Waukegan Road, North Chicago, IL, United States, 60064-6400 | http://www.abbvieinvestor.com |
India peptide antibiotics market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to peptide antibiotics market will help companies and investors design strategic landscapes.
Non-ribosomal synthesized peptide antibiotics was the largest segment with a revenue share of 78.42% in 2024. Horizon Databook has segmented the India peptide antibiotics market based on ribosomal synthesized peptide antibiotics, non-ribosomal synthesized peptide antibiotics covering the revenue growth of each sub-segment from 2018 to 2030.
Reasons to subscribe to India peptide antibiotics market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of India peptide antibiotics market databook
-
Our clientele includes a mix of peptide antibiotics market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the India peptide antibiotics market, including forecasts for subscribers. This country databook contains high-level insights into India peptide antibiotics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
India peptide antibiotics market report size, by product, 2018-2030 (US$M)
India Peptide Antibiotics Market Share, 2024 & 2030 (US$M)
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
